142 related articles for article (PubMed ID: 14520369)
1. Has gene therapy for ALS arrived?
Miller TM; Cleveland DW
Nat Med; 2003 Oct; 9(10):1256-7. PubMed ID: 14520369
[No Abstract] [Full Text] [Related]
2. Amyotrophic lateral sclerosis and gene therapy.
Miller TM; Smith RA; Cleveland DW
Nat Clin Pract Neurol; 2006 Sep; 2(9):462-3. PubMed ID: 16932606
[No Abstract] [Full Text] [Related]
3. VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model.
Azzouz M; Ralph GS; Storkebaum E; Walmsley LE; Mitrophanous KA; Kingsman SM; Carmeliet P; Mazarakis ND
Nature; 2004 May; 429(6990):413-7. PubMed ID: 15164063
[TBL] [Abstract][Full Text] [Related]
4. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model.
Kaspar BK; Lladó J; Sherkat N; Rothstein JD; Gage FH
Science; 2003 Aug; 301(5634):839-42. PubMed ID: 12907804
[TBL] [Abstract][Full Text] [Related]
5. Of mice, men and motor neurons.
Newbery HJ; Abbott CM
Trends Mol Med; 2002 Feb; 8(2):88-92. PubMed ID: 11815275
[TBL] [Abstract][Full Text] [Related]
6. Edaravone in ALS.
Takahashi R
Exp Neurol; 2009 Jun; 217(2):235-6. PubMed ID: 19285071
[No Abstract] [Full Text] [Related]
7. Increased survival and function of SOD1 mice after glial cell-derived neurotrophic factor gene therapy.
Acsadi G; Anguelov RA; Yang H; Toth G; Thomas R; Jani A; Wang Y; Ianakova E; Mohammad S; Lewis RA; Shy ME
Hum Gene Ther; 2002 Jun; 13(9):1047-59. PubMed ID: 12067438
[TBL] [Abstract][Full Text] [Related]
8. Gene Therapy for ALS: progress and prospects.
Azzouz M
Biochim Biophys Acta; 2006; 1762(11-12):1122-7. PubMed ID: 16806843
[TBL] [Abstract][Full Text] [Related]
9. Current developments in gene therapy for amyotrophic lateral sclerosis.
Scarrott JM; Herranz-Martín S; Alrafiah AR; Shaw PJ; Azzouz M
Expert Opin Biol Ther; 2015 Jul; 15(7):935-47. PubMed ID: 25959569
[TBL] [Abstract][Full Text] [Related]
10. Synergy of insulin-like growth factor-1 and exercise in amyotrophic lateral sclerosis.
Kaspar BK; Frost LM; Christian L; Umapathi P; Gage FH
Ann Neurol; 2005 May; 57(5):649-55. PubMed ID: 15852403
[TBL] [Abstract][Full Text] [Related]
11. RNAi therapy: dominant disease gene gets silenced.
Xu Z; Xia XG
Gene Ther; 2005 Aug; 12(15):1159-60. PubMed ID: 15858609
[No Abstract] [Full Text] [Related]
12. RNA interference protects against ALS in mouse model.
Burton A
Lancet Neurol; 2005 May; 4(5):274-5. PubMed ID: 15861555
[No Abstract] [Full Text] [Related]
13. Amyotrophic lateral sclerosis (motor neuron disease): proposed mechanisms and pathways to treatment.
Goodall EF; Morrison KE
Expert Rev Mol Med; 2006 May; 8(11):1-22. PubMed ID: 16723044
[TBL] [Abstract][Full Text] [Related]
14. Neuroprotective effect of oxidized galectin-1 in a transgenic mouse model of amyotrophic lateral sclerosis.
Chang-Hong R; Wada M; Koyama S; Kimura H; Arawaka S; Kawanami T; Kurita K; Kadoya T; Aoki M; Itoyama Y; Kato T
Exp Neurol; 2005 Jul; 194(1):203-11. PubMed ID: 15899257
[TBL] [Abstract][Full Text] [Related]
15. Experimental therapies hold promise for treating amyotrophic lateral sclerosis.
Friedrich MJ
JAMA; 2005 Mar; 293(9):1048-9. PubMed ID: 15741517
[No Abstract] [Full Text] [Related]
16. Are all new data referring to amyotrophic lateral sclerosis certain? Some doubts.
Rafałowska J
Folia Neuropathol; 2001; 39(4):261-4. PubMed ID: 11928897
[TBL] [Abstract][Full Text] [Related]
17. Coincident thresholds of mutant protein for paralytic disease and protein aggregation caused by restrictively expressed superoxide dismutase cDNA.
Wang J; Xu G; Slunt HH; Gonzales V; Coonfield M; Fromholt D; Copeland NG; Jenkins NA; Borchelt DR
Neurobiol Dis; 2005 Dec; 20(3):943-52. PubMed ID: 16046140
[TBL] [Abstract][Full Text] [Related]
18. Managing amyotrophic lateral sclerosis: slowing disease progression and improving patient quality of life.
Brooks BR
Ann Neurol; 2009 Jan; 65 Suppl 1():S17-23. PubMed ID: 19191306
[TBL] [Abstract][Full Text] [Related]
19. From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS.
Cleveland DW; Rothstein JD
Nat Rev Neurosci; 2001 Nov; 2(11):806-19. PubMed ID: 11715057
[No Abstract] [Full Text] [Related]
20. Determinants of rapid disease progression in ALS.
Yamanaka K; Cleveland DW
Neurology; 2005 Dec; 65(12):1859-60. PubMed ID: 16380607
[No Abstract] [Full Text] [Related]
[Next] [New Search]
